logo
  

Danaher Plans To Separate Environmental & Applied Solutions Segment

Danaher Corp. (DHR) said that it plans to separate its Environmental & Applied Solutions segment to create an independent, publicly traded company.

The new company will be comprised of Danaher's Water Quality and Product Identification businesses and will be referred to as "EAS" until it is named at a later date. The transaction is expected to be completed in the fourth quarter of 2023.

The company noted that Jennifer Honeycutt will become President and Chief Executive Officer of EAS upon completion of the transaction. Honeycutt joined Danaher in 1999 via the acquisition of Hach and she currently serves as a Danaher Executive Vice President with responsibility for the Environmental & Applied Solutions segment.

In a separate press release, Danaher said it expects third quarter 2022 core revenue growth to be above the company's prior guidance range. The increase is driven by higher Cepheid respiratory testing revenue, which is now anticipated to be greater than $500 million for the third quarter 2022 versus the prior expectation of approximately $325 million.

The company continues to expect base business core revenue growth to be in the high single digit range in the third quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT